Lamisil

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as a topical formulation for skin application. It penetrates the stratum corneum to reach the site of infection and is used to treat fungal infections of the skin, hair, and nails in both adults and children under medical supervision. Lamisil is indicated for common dermatophyte infections and is marketed in the European Union.

GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil is an allylamine antifungal indicated for dermatophyte infections of the skin, hair and nails.

- Tinea pedis: reduces fungal infection of the feet, relieving itching, scaling and redness. - Tinea corporis: clears ring‑shaped lesions on the body, diminishing inflammation and spread. - Tinea cruris: treats fungal infection of the groin area, alleviating irritation and rash. - Tinea unguium (onychomycosis): improves nail appearance by eradicating the causative fungus.

Topical terbinafine may cause local and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Skin irritation: mild redness or itching at the application site. - Burning sensation: transient warmth during use. - Dryness: peeling or flaking of treated skin. - Pruritus: occasional itching. - Erythema: mild redness. - Stinging: brief discomfort upon application.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, hives, or difficulty breathing. - Stevens‑Johnson syndrome: rare but serious skin blistering and detachment. - Liver enzyme elevation: systemic absorption may affect liver function. - Contact dermatitis: intense skin inflammation. - Anaphylaxis: life‑threatening hypersensitivity response.

When using Lamisil topical, consider the following precautions to ensure safe and effective treatment.

- Avoid application on broken skin: may increase systemic absorption. - Do not use with other topical antifungals without medical advice: risk of irritation. - Limit use to prescribed area: avoid eyes, mucous membranes, and genitalia unless directed. - Discontinue if severe irritation occurs: seek medical advice promptly. - Store at room temperature: keep in the original pack, protect from moisture and light.

Terbinafine topical can interact with certain systemic and topical agents; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent oral terbinafine therapy: may increase systemic exposure and risk of toxicity. - Use with potent CYP2D6 inhibitors: can alter terbinafine metabolism. - Co‑administration with other topical antifungals without guidance: risk of irritation.

Moderate Interactions (Monitor Closely): - Combination with topical corticosteroids: may mask local irritation. - Use with systemic hepatotoxic drugs: monitor liver function. - Application with other skin products (e.g., moisturizers) may affect absorption.